Recent Finacing
Recent Raise
Bioharmony Therapeutics develops lysin-based antimicrobials targeting multidrug-resistant Gram-negative pathogens (Acinetobacter baumannii, Klebsiella, E. coli), advancing topical and systemic candidates for skin, lung, bladder, and sepsis applications.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor